Literature DB >> 11296977

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.

S Merkesdal1, J Ruof, J L Huelsemann, O Schoeffski, A Maetzel, W Mau, H Zeidler.   

Abstract

The aim of our study was to comprehensively review and critically appraise the cost domains used in economic evaluations of the rheumatic diseases and to use this information to propose standardization of cost domains. The literature search identified 210 abstracts, 32 of which included original cost data. The listed cost categories were grouped into 3 major areas: (direct) health care costs, other (direct) disease related costs, and productivity costs (indirect costs). The number of individual cost categories was reduced by considering the following criteria: (1) inclusion of all relevant cost domains; (2) avoidance of double counting; (3) summarizing of related categories under one representative heading; (4) feasibility of level of aggregation. After adjustment for synonymous labeling, 38 cost categories remained. The subsequent development of a classification scheme of cost categories led to a set of 19 separate cost domains including 7 outpatient, 3 inpatient, 6 other disease related, and 3 productivity cost domains. This literature review indicates that cost assessment in economic evaluations in rheumatoid arthritis lacks standardization. A preliminary scheme to categorize cost assessment in rheumatic conditions is presented. The adoption of standards for economic evaluation would greatly facilitate national and international comparisons.

Entities:  

Mesh:

Year:  2001        PMID: 11296977

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  [Conceptual and methodological basics of cost assessments in rheumatology].

Authors:  J Ruof; J L Hülsemann; T Mittendorf; J-M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.

Authors:  Kalle Mattila; Frank Buttgereit; Risto Tuominen
Journal:  Rheumatol Int       Date:  2015-05-26       Impact factor: 2.631

4.  Direct costs related to rheumatoid arthritis: the patient perspective.

Authors:  J L Hülsemann; T Mittendorf; S Merkesdal; S Handelmann; J-M von der Schulenburg; H Zeidler; J Ruof
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

5.  Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.

Authors:  J L Hülsemann; J Ruof; H Zeidler; T Mittendorf
Journal:  Rheumatol Int       Date:  2005-11-01       Impact factor: 2.631

6.  [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].

Authors:  S Merkesdal; J L Huelsemann; T Mittendorf; S Zeh; H Zeidler; J Ruof
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

7.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

8.  Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards.

Authors:  Jörg Ruof; Jan L Hülsemann; Thomas Mittendorf; Silke Handelmann; Rick Aultman; J Matthias von der Schulenburg; Henning Zeidler; Sonja Merkesdal
Journal:  Eur J Health Econ       Date:  2004-02

9.  Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.

Authors:  Tae-Jin Lee; Bo-Hyun Park; Joon Wan Kim; Kichul Shin; Eun Bong Lee; Yeong-Wook Song
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.